Skip to main content
. Author manuscript; available in PMC: 2015 Apr 21.
Published in final edited form as: J Immunol. 2011 Jul 8;187(4):1634–1642. doi: 10.4049/jimmunol.1100077

FIGURE 5.

FIGURE 5

LCMV-specific CD8 T cell viability after cotreatment with high or low dose of anti–4-1BB together with PD-L1 blockade. Experimental set-up as in Figs. 1A or 2A. A, FACS plot showing the percentage of splenic Dbgp276–286-specific CD8 T cells that are apoptotic or alive by annexin V/7AAD staining in spleen at days 7 and 14 posttreatment. B, Percent of Dbgp276–286-specific CD8 T cells that are positive for both annexin V and 7AAD (apoptotic population). C, Percentage of Dbgp276–286-specific CD8 T cells that are negative for both annexin V and 7AAD (42). *p < 0.05. Experiments were repeated three times.